Platinum-Resistant Ovarian Carcinoma

subtype

Identifier: CI-CAN-00006442
Entity page: /cancer/platinum-resistant-ovarian-carcinoma ↗
Edges: 153

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Platinum-Resistant Ovarian Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 44show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 20 trials (11 active) · roll-up of the cancer and its descendants	—	—	Platinum-Resistant Ovarian Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumab

Platinum-Resistant Ovarian Carcinoma studied in …STUDIED_INderived10 of 109show all (up to 200)
→ studied in	NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07265739Phase 2 · not yet recruiting Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07489287Phase 1 · recruiting GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04633239Phase 1 · recruiting Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05081609Phase 1/Phase 2 · active not recruiting A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06964009Phase 1 · recruiting DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07604766Phase 3 · recruiting An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China · condition mapped ALIAS · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04585958Phase 1 · recruiting Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 109 trials mapped (56 active)	—	—	Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains